PropThink: ENDP’s Lower Guidance Not Much Of A Surprise; Negative Sentiment Remains An Opportunity

[ACN Newswire] – By David MoskowitzEndo Pharmaceuticals (NASDAQ:ENDP) reported 3Q 2012 adjusted EPS of $1.28, ahead of the Consensus estimate of $1.26. However, revenues for the period came in at $750.5 million vs. Street … more

View todays social media effects on ENDP

View the latest stocks trending across Twitter. Click to view dashboard